Replimune Group, Inc. (REPL): Price and Financial Metrics
REPL Price/Volume Stats
| Current price | $7.47 | 52-week high | $29.52 |
| Prev. close | $6.75 | 52-week low | $5.89 |
| Day low | $6.68 | Volume | 1,777,466 |
| Day high | $7.50 | Avg. volume | 684,117 |
| 50-day MA | $13.11 | Dividend yield | N/A |
| 200-day MA | $18.11 | Market Cap | 441.17M |
REPL Stock Price Chart Interactive Chart >
Replimune Group, Inc. (REPL) Company Bio
Replimune Ltd. develops oncolytic immunotherapies for the treatment of cancer. It is developing various proprietary products intended to enhance the direct anti-tumor effects of selective virus replication and the potency of the immune response to the tumor antigens released. The company was founded in 2015 is based in Abingdon, the United Kingdom.
Latest REPL News From Around the Web
Below are the latest news stories about REPLIMUNE GROUP INC that investors may wish to consider to help them evaluate REPL as an investment opportunity.
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma ResearchRP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated diseaseWOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated data from a cohort of metastatic uveal melanoma patients enrolled in the open-label, multicent |
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate UpdateThe Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined with Libtayo in cutaneous squamous cell carcinomaAn initial data snapshot for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanomaInitial data from the IGNYTE cohort of RP1 in anti-PD1 failed non-melanoma skin cancersA recap of interim data from the ARTACUS clinical trial |
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patientsWOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced updated interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid |
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the grant of inducement equity awards to Emily Hill, the Company’s newly appointed Chief Financial Officer. The inducement awards consist of a non-qualified stock option to purchase 125,000 shares of the Company's common stock and restricted stock units representing 83,330 share |
Replimune Announces Appointment of Emily Hill as Chief Financial OfficerWOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the appointment of Emily Hill as Chief Financial Officer. Ms. Hill was most recently CFO of the commercial stage biotech company PTC Therapeutics and has more than 15 years of experience in the biotechnology and life sciences industry having held senior financial management and |
REPL Price Returns
| 1-mo | -41.96% |
| 3-mo | -61.89% |
| 6-mo | -66.76% |
| 1-year | -60.46% |
| 3-year | -84.03% |
| 5-year | -47.84% |
| YTD | -72.54% |
| 2022 | 0.37% |
| 2021 | -28.96% |
| 2020 | 165.85% |
| 2019 | 43.50% |
| 2018 | N/A |
Loading social stream, please wait...